Bristol-Meyers Squibb: Treating Hepatitis B in Russia
Bristol-Meyers Squibb hired PBN Hill+Knowlton Strategies to introduce and secure market access for its new medicine against chronic Hepatitis B in Russia, including facilitating the product’s inclusion in state-budgeted programs and lists.
PBN H+K Strategies launched a comprehensive education and outreach program to patients' associations and other stakeholders to raise awareness of problems associated with Hepatitis B in Russia. We led an advocacy program among relevant government bodies on the efficacy of the company's medicines. The product was successfully registered in Russia in May 2007 and included, by government decree, in the List of Purchased Medicines for Treating Co-Infections of HIV/AIDS.